From Sweden to Silicon Valley: How OnDosis is Tackling the U.S. Market at JPM 2026
By Rebeca Varela Lores, Investment Associate
February 3, 2026
The 44th Annual J.P. Morgan Healthcare Conference held in San Francisco between January 12–15, 2026 remains the industry’s premier investment symposium, attracting over 8,000 global leaders, emerging fast-growth companies, and members of the investment community. This year, the atmosphere was one of "cautious optimism", with high-stakes discussions focusing on the AI revolution in drug discovery, navigating impending patent cliffs, and the vital role of transatlantic partnerships in scaling innovation.
Against this backdrop of "brutally hectic" deal-making and networking, Martin Olovsson shared how OnDosis, a Swedish spin-off from AstraZeneca, is navigating its own path toward a major U.S. launch.
Part I - The Rigorous Road to Precision: Martin Olovsson on Navigating the U.S. Market
Martin Olovsson provides a rare look into the rigorous seven-year preparation behind the company's strategic entry into the U.S. market. He emphasizes the essential "handshake" between innovative hardware, digital services, and deep qualitative market research. This segment captures the essence of a leader navigating the complex global "village" to accelerate real-world patient impact.
Part II - The "Holy Grail" of Precision Dosing — Bridging Needs and Innovation
In this second segment, Martin Olovsson explores the core mission of OnDosis: revolutionizing the fundamental way patients take their medication. He identifies critical unmet needs for precision dosing in neglected areas such as pediatrics, women’s health, and psychiatry. The discussion features a powerful analogy, comparing traditional fixed-dose pills to outdated typewriters versus the modern "iPad" approach of OnDosis technology. Martin shares a standout moment from the conference where an investor described their work as the "Holy Grail" of precision dosing. He details the strategic importance of navigating objections from payers and pharmacies while securing interest from elite U.S. and Nordic investors. Finally, he credits the firm's market credibility to its deep-rooted heritage as an AstraZeneca spin-off and the collaborative BioVentureHub ecosystem.
Part III - Roadmap to 2028 — Tailoring Precision Dosing for the U.S. Market
Looking ahead to a 2028 U.S. launch, Martin Olovsson details OnDosis’s strategic roadmap, led by its flagship ADHD program. Central to this journey is the "dosage manager", an intelligent drug-device combination that replaces rigid, traditional protocols with flexible, precise titration. By moving beyond a one-size-fits-all approach, the technology aims to solve the root causes of patient non-adherence and dissatisfaction, offering life-changing benefits for children starting treatment and women needing to adjust doses across monthly cycles. The scope of this innovation extends to high-stakes fields like Parkinson’s, epilepsy, and pediatric oncology, where narrow therapeutic windows demand extreme accuracy. This ambitious evolution is anchored by a commercial "handshake" between OnDosis’s Gothenburg headquarters and the American market, supported by partners like Business Sweden to ensure a successful transatlantic entry.